文献速递胸部肿瘤

外显子16跳跃型HER2作为奥希替尼耐药新机制

Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2019-09-23

本研究基于一例EGFR L858R/T790M阳性NSCLC患者奥希替尼耐药后血浆游离DNA检出外显子16跳跃型HER2(HER2D16)的发现,构建稳定表达HER2D16的H1975细胞模型,探究其作为奥希替尼耐药机制的作用。结果显示HER2D16可形成同源二聚体,使H1975细胞对奥希替尼耐药,且突变EGFR与HER2D16协同激活下游信号;Src激酶抑制剂不能逆转耐药,提示为非经典Src非依赖通路;奥希替尼联合泛HER小分子抑制剂阿法替尼可协同抑制H1975-HER2D16细胞生长和信号传导。结论认为HER2D16通过Src非依赖途径参与奥希替尼耐药,应纳入肺癌分子诊断面板。

要点

  • HER2D16使EGFR L858R/T790M阳性NSCLC细胞对奥希替尼耐药
  • HER2D16驱动耐药不依赖Src激酶,Src抑制剂联合奥希替尼不能逆转耐药
  • 奥希替尼联合阿法替尼可协同抑制HER2D16表达细胞的生长和信号

核心结论

  • HER2D16可通过Src非依赖途径导致EGFR L858R/T790M阳性NSCLC对奥希替尼耐药。
  • 建议将HER2D16纳入肺癌分子诊断面板。

研究设计与样本

  • 基于一例奥希替尼耐药患者血浆游离DNA分析发现HER2D16的病例,构建稳定表达HER2D16的H1975细胞系进行体外研究。
  • 采用非还原聚丙烯酰胺凝胶电泳检测HER2D16二聚体形成,Western blot检测信号传导,Chou-Talalay法评估药物协同效应。

主要发现

  • HER2D16可在NSCLC细胞中形成同源二聚体。
  • 表达HER2D16的H1975细胞对奥希替尼治疗耐药。
  • 突变EGFR与HER2D16协同激活下游信号导致奥希替尼耐药。
  • 奥希替尼联合Src激酶抑制剂未能逆转耐药。
  • 奥希替尼联合阿法替尼可协同抑制H1975-HER2D16细胞生长和信号传导。

临床怎么用

  • 对奥希替尼耐药的EGFR L858R/T790M阳性NSCLC患者,可考虑检测HER2D16以明确耐药机制。
  • HER2D16介导的耐药可能对奥希替尼联合阿法替尼敏感,但需临床研究验证。

局限性

  • 研究主要基于体外细胞模型,尚未在临床队列中验证HER2D16的发生频率和靶向治疗疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib is the current recommended treatment for EGFR T790M-positive NSCLC after EGFR tyrosine kinase inhibitor therapy. However, resistance to osimertinib therapy is inevitably acquired after a period of effective treatment. We had a patient with EGFR L858R/T790M-positive NSCLC who initially responded to osimertinib therapy but eventually experienced development of resistance. Plasma cell-free DNA analysis revealed the occurrence of exon 16-skipping HER2, which may have resulted in the erb-b2 receptor tyrosine kinase 2 gene (HER2) splice variant HER2D16. HER2D16 has never been reported in lung cancer, and HER2D16-driven signaling is known to be regulated by Src kinase in breast cancer. We investigated the role of HER2D16 as an osimertinib-resistant mechanism. METHODS: We constructed and established H1975 cells stably expressing HER2D16. The dimeric formation of HER2D16 was tested by using nonreducing polyacrylamide gel electrophoresis. The effects of the study drugs on signaling transduction were examined by using Western blot. Synergistic effect was assessed by using the Chou-Talalay method. RESULTS: We found that HER2D16 can form a homodimer in NSCLC cells. HER2D16-expressing H1975 cells were resistant to osimertinib treatment. We also found that mutant EGFR and HER2D16 cooperated to activate downstream signaling for osimertinib resistance. In addition, cotreatment with osimertinib and an Src kinase inhibitor failed to reverse resistance, indicating that HER2D16-driven signaling in NSCLC did not occur through a canonical pathway. Finally, we revealed that the combination of osimertinib with the pan-HER small-molecule inhibitor afatinib could synergistically repress cell growth and signaling in H1975-HER2D16 cells. CONCLUSION: HER2D16 can contribute to osimertinib resistance through an Src-independent pathway. HER2D16 should be included in the molecular diagnosis panel for lung cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hsu CC, Liao BC, Liao WY, et al. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2019. PMID: 31557536. doi:10.1016/j.jtho.2019.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。